EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 523 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR In Memory of Håkan Mellstedt: Former ESMO President August 26, 2025 2023 Highlights in Treating Genitourinary Cancers: Expert Perspectives January 24, 2024 Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant... October 4, 2024 Over 600 people in England set to benefit from innovative lung... December 1, 2021 Load more HOT NEWS New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines Frederick National Laboratory for Cancer Research: A Unique Resource for the... FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for... The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer...
